Invitro International (IVRO) research, news, and more from GeoInvesting

Company description

Tue, 20 Jan 2026 18:02:39 GMT

InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company also provides customized technology services for Irritection Assay System installation and testing process, and independent testing laboratory services for irritancy and corrosivity testing requirements, as well as consultation and assistance services. Its products are principally used in cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, hazardous waste, and transportation industries. InVitro International, Inc. was incorporated in 1985 and is headquartered in Placentia, California.

Research

Tue, 05 May 2026 20:28:19 GMT

Invitro International (OTCQB:IVRO) ($0.08; $1.9M market cap) announced Q2 FY2026 results:

Q2 FY26 sales of $206,840 up 5% year over year

“Our second quarter financials were brighter than 1Q '26; they advanced over last year in both sales and net income. InVitro is aiming for its 21st consecutive year of profitability while also making progress in its new strategic direction. We continue to find prospects globally who are just learning of regulatory policies changing toward acceptance of in vitro test results. The future remains bright and more encouraging than ever."

Our Quick Take:

We are awaiting the 10-Q filing to see if there is any update regarding the MOU announced in January 2025 to merge with a European-based non-animal testing organization. We also want to check on the cash per share, which was near $0.06 per share last quarter.

InVitro International, Inc. develops and sells non-animal in vitro test kits and laboratory services used to assess the irritancy and corrosivity of chemicals and product formulations.

Research

Wed, 11 Feb 2026 17:29:02 GMT

InVitro International (OTCQB:IVRO) ($0.11; $2.4M market cap) announced Q1 FY2026 results:

Q1 FY26 sales of $182,600 vs $244,144 in the prior year
Q1 FY26 EPS: $0.001 vs $0.001 in the prior year

Management Commentary:

"Our first quarter financials, though positive, do not reflect the many global Regulatory/Government statements encouraging in vitro testing over the past year. That acknowledged, we cannot recall in our 40 years a time when there is more support from both citizens and Government Agencies to replace animal testing with validated non-animal test methods. We remain steadfast in our beliefs for the future & look forward to our FY'26 second Quarter." – Chairman & CEO, W. Richard Ulmer

Our Quick Take:

Sales and EPS results were disappointing. We are also concerned that the company has not provided any additional updates regarding the MOU announced in January 2025 to merge with a European-based non-animal testing organization.

However, management stated that the regulatory environment is positive, suggesting results will improve in the next quarters.

Our main concern is that the company doesn’t really have a sales organization/team beyond the CEO. So even if the regulatory backdrop keeps moving in their favor, it may not matter unless he builds out a real go-to-market effort and executes a more aggressive marketing strategy.

InVitro International, Inc. develops and sells non-animal in vitro test kits and laboratory services used to assess the irritancy and corrosivity of chemicals and product formulations.

Research

Tue, 20 Jan 2026 18:18:50 GMT

**Call To Action: IVRO - An Extremely Speculative Idea We Are Adding to the Run to $1 Model Portfolio [PodClip]

Maj just dropped a new PodClip focused on Invitro International (OTCQB:IVRO), a tiny, extremely speculative, OTC name that sits in the non-animal testing niche. Think eye and skin irritation testing without using animal tissue. In the clip, he considers IVRO as a Run-to-$1 Radar idea: not a fully-baked pitch yet, but a “watchlist / early due diligence” setup with cash on the balance sheet, a profitable baseline, and optionality if regulatory momentum toward non-animal methods (and potential strategic moves like partnerships or M&A) starts to translate into real growth.

Listen to the IVRO PodClip here! (must be signed in)